FOXO1 and PAX5 Rearrangement in Alveolar Rhabdomyosarcoma in Saudi Pediatric Patients

References

• Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 2006;130(10):1454–65. doi:10.5858/2006-130-1454-RIAACA.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MCG, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European Cooperative Groups. J Clin Oncol. 2008;26(14):2384–9. doi:10.1200/JCO.2007.14.7207.
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PHB, et al. Molecular classification of rhabdomyosarcoma – genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am J Pathol. 2009;174(2):550–64. doi:10.2353/ajpath.2009.080631.
   PubMed Web of Science ®Google Scholar
• Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Houghton JA, Green AA. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet. 1987;45(3–4):148–55. doi:10.1159/000132446.
   PubMedGoogle Scholar
• Shukla N, Ameur N, Yilmaz I, Nafa K, Lau C-Y, Marchetti A, Borsu L, Barr FG, Ladanyi M. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18(3):748–57. doi:10.1158/1078-0432.CCR-11-2056.
   PubMed Web of Science ®Google Scholar
• Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, Pawel BR. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol. 2009;12(4):275–83. doi:10.2350/08-03-0434.1.
   PubMed Web of Science ®Google Scholar
• Pillay K, Govender D, Chetty R. ALK protein expression in rhabdomyosarcomas. Histopathology. 2002;41(5):461–7. doi:10.1046/j.1365-2559.2002.01534.x.
   PubMed Web of Science ®Google Scholar
• Kaleta M, Wakulińska A, Karkucińska-Więckowska A, Dembowska-Bagińska B, Grajkowska W, Pronicki M, Łastowska M. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Diagn Pathol. 2019;14(1). doi:10.1186/s13000-019-0883-4.
   PubMed Web of Science ®Google Scholar
• Raghavan SS, Mooney KL, Folpe AL, Charville GW. OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma. Hum Pathol. 2019;91:77–85. doi:10.1016/j.humpath.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, Rauscher FJ. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol. 1995;15(3):1522–35. doi:10.1128/MCB.15.3.1522.
   PubMed Web of Science ®Google Scholar
• Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20(40):5736–46. doi:10.1038/sj.onc.1204599.
   PubMed Web of Science ®Google Scholar
• Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3(2):113–17. doi:10.1038/ng0293-113.
   PubMed Web of Science ®Google Scholar
• Lovell MA, D’Cruz CM, Barr FG. Fusion of PAX7 to FKHR by the variant t(l;13)(p36;ql4) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869–72.
   PubMed Web of Science ®Google Scholar
• Sorensen PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children’s Oncology Group. J Clin Oncol. 2002;20(11):2672–9. doi:10.1200/JCO.2002.03.137.
   PubMed Web of Science ®Google Scholar
• Wang Q, Fang W-H, Krupinski J, Kumar S, Slevin M, Kumar P. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008;12(6A):2281–94. doi:10.1111/j.1582-4934.2008.00427.x.
   PubMed Web of Science ®Google Scholar
• Sullivan LM, Atkins KA, Legallo RD. PAX immunoreactivity identifies alveolar rhabdomyosarcoma. Am J Surg Pathol. 2009;33(5):775–80. doi:10.1097/PAS.0b013e318191614f.
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, Gibson S, Sebire NJ, Anderson J. PAX5 expression in rhabdomyosarcoma. Am J Surg Pathol. 2009;33(10):1575–7. doi:10.1097/PAS.0b013e3181abe137.
   PubMed Web of Science ®Google Scholar
• Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010;70.
   Web of Science ®Google Scholar
• Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri S, Gryder B, Oliveira ML, Ramakrishnan A, Tang Q, et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife. 2017;6. doi:10.7554/eLife.19214. .
   PubMed Web of Science ®Google Scholar
• Skrzypek K, Kusienicka A, Trzyna E, Szewczyk B, Ulman A, Konieczny P, Adamus T, Badyra B, Kortylewski M, Majka M, et al. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function. Cell Death Dis. 2018;9(6) doi:10.1038/s41419-018-0693-8. .
   PubMedGoogle Scholar
• Austin PC, Tu JV. Bootstrap methods for developing predictive models. Am Stat. 2004;58(2):131–7. doi:10.1198/0003130043277.
   Web of Science ®Google Scholar
• Gong H-B, Wu X-J, Pu X-M, Kang X-J. Bioinformatics analysis of key biomarkers and pathways in KSHV infected endothelial cells. Medicine (Baltimore). 2019;98(27):e16277. doi:10.1097/MD.0000000000016277.
   PubMed Web of Science ®Google Scholar
• Hanafi H, Hassani BDR, Kbir MA. Biological networks analysis, analytical approaches and use case on protein–protein network interactions. Proceedings of the 4th International Conference on Smart City Applications; 2019. doi:10.1145/3368756.3368996.
   Google Scholar
• Qiu L, Wang T, Ge Q, Xu H, Wu Y, Tang Q, Chen K. Circular RNA signature in hepatocellular carcinoma. J Cancer 2019;10(15):3361–3372. doi:10.7150/jca.31243.
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. Human FOX gene family (Review). Int J Oncol. 2004;25(5):1495–500. doi:10.3892/ijo.25.5.1495.
   PubMed Web of Science ®Google Scholar
• Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67(17):8293–300. doi:10.1158/0008-5472.CAN-07-1265.
   PubMed Web of Science ®Google Scholar
• Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S, Xie K, et al. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012;72(3):655–65. doi:10.1158/0008-5472.CAN-11-3102.
   PubMed Web of Science ®Google Scholar
• Fan R. PAX immunoreactivity in poorly differentiated small round cell tumors of childhood. Fetal Pediatr Pathol. 2014;33(4):244–52. doi:10.3109/15513815.2014.920441.
   PubMed Web of Science ®Google Scholar
• Liu W, Li X, Chu ESH, Go MYY, Xu L, Zhao G, Li L, Dai N, Si J, Tao Q, et al. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology. 2011;53(3):843–53. doi:10.1002/hep.24124.
   PubMed Web of Science ®Google Scholar
• Qin G, Sun Y, Guo Y, Song Y. PAX5 activates telomerase activity and proliferation in keloid fibroblasts by transcriptional regulation of SND1, thus promoting keloid growth in burn-injured skin. Inflamm Res. 2021;70(4):459–72. doi:10.1007/s00011-021-01444-3.
   PubMed Web of Science ®Google Scholar
• Haghverdi MK, Moslemi E. Expression rate and PAX5 gene methylation in the blood of people suffering from gastric cancer. Open Access Maced J Med Sci. 2018;6(9):1571–6. doi:10.3889/oamjms.2018.269.
   PubMedGoogle Scholar
• Liu SL, Cai C, Yang ZY, et al. Dgcr5 is activated by pax5 and promotes pancreatic cancer via targeting mir-3163/top2a and activating wnt/β-catenin pathway. Int J Biol Sci. 2021;17.
   Web of Science ®Google Scholar